FAQs

These FAQs should be read in conjunction with the Amicus Ignite Terms and Conditions.
Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare diseases.

Amicus Therapeutics is committed to improving the lives of people living with Pompe disease and their caregivers. A core tenet of this commitment is close partnership with patient communities, ensuring that their needs are truly incorporated into the delivery of holistic care.
Amicus has engaged a third-party service provider called Publicis Langland to assist with the administration of the Amicus Ignite programme.
Amicus Ignite is a proactive community funding programme for initiatives that support people living with Pompe disease.

We invite applications from across the Pompe community, including healthcare institutions, patient advocacy organisations, academic institutions and charitable organisations to support and improve the lives of those impacted by Pompe disease. Currently, applications are only open to organisations and projects located outside of the United States.

Applications to Amicus Ignite should be innovative, scalable, replicable and sustainable and aim to make a tangible difference to people living with Pompe. Funding of up to €20,000 (or local currency equivalent) for a limited number of projects is available. Projects need to be completed in one year from the receipt of funding and create lasting change for those impacted by Pompe disease.
Amicus Ignite invites applications from across the Pompe disease and wider neuromuscular community including:

  • Hospitals and other healthcare institutions promoting patient care
  • Academic institutions engaged in life science innovation
  • Patient advocacy organisations (PAOs)
  • Charitable organisations

Currently, applications are only open to organisations and projects located outside of the United States.

A detailed list of inclusion and exclusion criteria can be found in the “What are the inclusion and exclusion criteria for the programme?” question below.
Funding of up to €20,000 (or local currency equivalent) for a limited number of projects is available. Projects need to be completed in one year from the receipt of the funding and create lasting change for those impacted by Pompe disease. The amount available for each project will depend on several factors, such as the budget breakdown of each request.
We invite applications from across the Pompe disease community, including healthcare institutions, patient advocacy organisations, and academic institutions to support and improve the lives of those impacted by Pompe disease.

Examples of types of proposals that are appropriate for Amicus Ignite include, but are not limited to:
  1. Disease information animation
  2. Learning programmes
  3. Disease management platforms unrelated to medicinal treatment

Applications for projects that relate to a particular medicinal treatment or Amicus products are not permitted and will not be funded.

Projects related to advancing medical research will not be funded by Amicus Ignite. Questions about research should be directed to Elizabeth Minas (Associate Director, International Medical Affairs at Amicus Therapeutics) via eminas@amicusrx.com.

Unfortunately, those looking for individual or PhD funding are not eligible to apply to this funding programme.

Funding cannot be awarded to ongoing or retrospective projects.

Projects or initiatives supported by funding must be started and completed within a maximum 12-month period following the receipt of funding. Funding will be provided for a maximum of one year.
Eligible applications will undergo a review process and an expert panel of clinicians, patient organisation representatives and Amicus stakeholders will evaluate the applications and make decisions concerning successful proposals.

The selection process will be co-ordinated by Publicis Langland, a third-party service provider engaged by Amicus.
Each application should reflect four key criteria to maximise the chances of a successful application:

Innovative
  • A creative and original idea that offers a new solution or approach to solving a problem or fulfilling an unmet need. It challenges conventional thinking and can lead to breakthroughs in processes or systems.

Scalable
  • An idea that has the potential to grow and expand efficiently without a corresponding increase in costs or resources. It can be extended to larger geographies, operations or audiences.

Replicable
  • The idea can be easily repeated or reproduced in different contexts or locations with consistent results. It typically follows a clear and structured process, allowing others to implement it successfully without significant changes.

Sustainable
  • A sustainable idea is one that meets present needs without compromising the ability of future generations to meet their own, balancing economic, social, and environmental considerations.

Applications should aim to make a tangible difference to people living with Pompe disease.

A detailed list of inclusion and exclusion criteria can be found in “What are the inclusion and exclusion criteria for the programme?” question below.
The following criteria are designed to ensure a fair and consistent assessment process. Both inclusion and exclusion criteria have been designed to highlight key aspects that align with the goals and standards of the programme, enabling a thorough and standardised evaluation of all applications.

Inclusion criteria
  • Applications must be in English
  • The request is from an established organisation e.g. a registered charity, or an organisation that has been involved in Pompe disease for a number of years
  • The applicant organisation must be able to legally receive funding directly from Amicus Therapeutics UK Limited. We cannot pay funding to organisations that do not hold recognised legal status and which do not have a bank account in the name of the organisation
  • The request is aligned to Amicus Ignite topics and objectives
  • The request has measurable outcomes
  • There is a clear budget breakdown
  • Project deliverables and metrics are clear and obvious
  • The timeline clearly shows that it can be delivered within a 12-month period
Exclusion criteria
  • The request is for core funding of an organisation
  • The request is for the funding of an individual or a PhD
  • The request for funding is for IT equipment, hospitality or permanent staffing costs
  • The request is linked to a specific medicine or potentially linked to commercial objectives or purpose
  • The request is for purchasing genetic testing or medicine
  • The request is for a clinical trial or phase 4 study
  • The request is for the cost of setting up a new charity
  • Amicus is the sole funder of the organisation’s full operating income
  • The request is for an existing or ongoing project
  • The project extends beyond the 12-month time-limit for the programme
  • The funding requested represents more than 30% of the applicant’s total funding for the year
 

The application window will open early 2025 and close on 31 May 2025.

Completed application forms and cover letters should be uploaded via the submission’s portal no later than 31 May 2025.

Applications must be submitted in English.

We cannot accept applications that are not uploaded to the submissions portal.

You can submit your application here.

Currently, applications are only open to organisations and projects located outside of the United States.

Yes, up to two applications from the same organisation can be submitted. Each application must be for separate projects and have no common project team members.

Applicants will be informed of the outcome of their submission at the end of summer 2025.

Funding recipients will be required to provide:

  • A report halfway through the funding year summarising project outcomes, performance against project metrics, reflections on progress and key insights, subject to local regulations.
  • A final summary of the project and outcomes at the end of the 12-month funding period, subject to local regulations.


Amicus will publish details of successful projects on the Amicus Ignite website, once recipients have been chosen and informed.

You will not receive feedback should your application be unsuccessful. However, you may apply again in subsequent years.

Should you have questions or need further information, please contact us at: amicus.ignite@langland.co.uk
Still have questions?
Contact us

NP-NN-UK-00040325. © March 2025. All rights reserved.